Table 4 Univariate analysis of factors influencing 140-day survival among patients in whom initial TAE was successfully performed (n = 15).

Patients (n)

9

6

Age (years)

67.1 ± 6.1

68.8 ± 8.2

NS

Sex (n, %)

   Male

8 (89%)

5 (83%)

NS

   Female

1 (11%)

1 (17%)

Etiology of LC (n, %)

   HCV

5 (56%)

5 (83%)

   HBV

1 (11%)

0 (0%)

NS

   Alcohol

1 (11%)

0 (0%)

   NonB-NonC

2 (22%)

1 (17%)

Past history of HCC treatment (n, %)

   presence

8 (89%)

4 (67%)

NS

   absence

1 (11%)

2 (33%)

Admission duration for treatment of HCC

3.6 ± 3.1

1.7 ± 1.6

NS

Months from first treatment of HCC

22.6 ± 21.9

27.0 ± 24.6

NS

Shock (n, %)

   presence

3 (33%)

3 (50%)

NS

   absence

6 (67%)

3 (50%)

Albumin (g/dL)

3.3 ± 0.4

3.4 ± 0.3

NS

Total bilirubin (mg/dL)

1.5 ± 0.7

1.6 ± 0.6

NS

PT (INR)

1.30 ± 0.19

1.29 ± 0.15

NS

ICG at 15 min (%)

35.1 ± 17.1

32.0 ± 11.0

NS

AFP (ng/ml)

1686

250

NS

PIVKA-II (mAU/mL)

7186

7758

NS

Ascites (n, %)

   presence

5 (56%)

4 (67%)

NS

   absence

4 (44%)

2 (33%)

Hepatic encephalopathy (n, %)

   presence

4 (44%)

4 (67%)

NS

   absence

5 (56%)

2 (33%)

AST (IU/L)

86 ± 59

66 ± 41

NS

ALT (IU/L)

58 ± 39

46 ± 33

NS

Hemoglobin (g/dL)

12.7 ± 1.4

11.7 ± 2.4

NS

Platelet count (× 10⁴)

16.7 ± 12.3

16.4 ± 9.5

NS

Creatinine (mg/dL)

0.80 ± 0.14

0.86 ± 0.16

NS

Child-Pugh classification (n, %)

   A

3 (33%)

2 (33%)

   B

4 (45%)

2 (33%)

NS

   C

2 (22%)

2 (33%)

Child-Pugh score

7.7 ± 2.0

8.0 ± 2.1

NS

Number of tumors (n, %)

   single

2 (22%)

1 (17%)

NS

   multiple

7 (78%)

5 (83%)

Maximum tumor size (cm)

7.4 ± 1.7

6.3 ± 3.3

NS (p = 0.1221)

Maximum tumor size (n, %)

   ≤ 7 cm

1 (11%)

5 (83%)

p = 0.0052

   > 7 cm

8 (89%)

1 (17%)

Portal vein tumor thrombosis

   presence

6 (67%)

1 (17%)

NS (p = 0.0572)

   absence

3 (33%)

5 (83%)

Clinical stage

   II, III

5 (56%)

5 (83%)

NS

   IVA, IVB

4 (44%)

1 (17%)